GLP-1 for IIH (Pseudotumor Cerebri): Mitchell Exenatide RCT + Weight Loss

Idiopathic intracranial hypertension (IIH), historically called pseudotumor cerebri, is a syndrome of elevated cerebrospinal-fluid pressure without a mass lesion or hydrocephalus, occurring almost exclusively in obese reproductive-age women. The standard treatment stack — weight loss, acetazolamide, topiramate, therapeutic lumbar puncture, and surgical decompression for vision-threatening disease — now has a new mechanism- specific addition. The IIH-Pressure trial (Mitchell JL et al., 2023, Brain^[1]) randomized adult women with IIH to subcutaneous exenatide 10 mcg twice daily or placebo for 12 weeks and reported a 5.7 cm H₂O ICP reduction on telemetric monitoring — an effect that appeared at the 2.5-hour post-dose timepoint, before any meaningful weight change. This article walks through what the trial showed, what the IIH pathway looks like in practice, and how a GLP-1 fits alongside acetazolamide, topiramate, and the surgical options.

The honest summary

• IIH is an obesity-driven syndrome. Annual incidence in obese reproductive-age women approaches 20/100,000 vs roughly 1/100,000 in the general population. The Adderley 2019 JAMA Neurology UK cohort^[8] also documented elevated cardiovascular risk in women with IIH, underscoring that this is a systemic metabolic disease, not just a neuro-ophthalmologic one.
• Weight loss is the primary disease-modifying treatment. Sinclair 2010 (BMJ prospective cohort^[2]) showed that a low-energy diet producing a sustained 15.7% weight loss reduced ICP, papilledema, and headache — the cornerstone observation that pre-dated the GLP-1 era.
• Acetazolamide is the first-line drug. The NORDIC IIH Treatment Trial (Wall 2014, JAMA^[3]) randomized patients with mild visual loss to acetazolamide (titrated to a mean of about 2.5 g/day) plus diet vs placebo plus diet, and found a small but statistically significant improvement in perimetric mean deviation at 6 months on acetazolamide.
• Exenatide is the first GLP-1 with a positive IIH-specific RCT. The IIH-Pressure trial (Mitchell 2023^[1]) is small (n=15 active, 16 placebo) but mechanistically clean: the ICP signal at 2.5 hours post-dose is independent of weight change. The mechanism is preclinically supported by Botfield 2017 (Sci Transl Med^[5]), which localized GLP-1 receptors on the choroid plexus epithelium and showed reduced CSF secretion in a rat hydrocephalus model.
• Vision-threatening disease is a surgical decision, not a medication decision. Optic nerve sheath fenestration (ONSF), venous sinus stenting, and ventriculo- peritoneal shunting remain the answer for rapid visual deterioration. GLP-1 therapy is an adjunct after the structural problem is addressed.

The diagnostic pathway: modified Dandy criteria and what to rule out

The diagnosis of pseudotumor cerebri syndrome is anchored in the revised Friedman–Liu–Digre criteria (Friedman 2013, Neurology^[4]), often called the modified Dandy criteria. The required elements are: symptoms and signs attributable to elevated intracranial pressure (most commonly papilledema), no localizing neurologic findings except unilateral or bilateral abducens nerve palsy, neuroimaging without evidence of mass, hydrocephalus, or venous sinus thrombosis, normal CSF composition, and an elevated lumbar puncture opening pressure — ≥ 25 cm CSF in adults in the lateral decubitus position with legs extended.

The neuroimaging workup is non-negotiable. Magnetic resonance venography (MRV) is the safest way to exclude cerebral venous sinus thrombosis, which can present identically to IIH and which is dangerous to miss. MRI findings supportive of IIH include posterior globe flattening, partially empty sella, distended optic nerve sheaths, and transverse sinus stenosis, though none of these are required for the diagnosis. Fluoroscopic guidance for the lumbar puncture is preferred when body habitus makes a blind LP technically difficult, because an inaccurate opening pressure is the single most common reason a patient is incorrectly labeled with or without IIH.

What IIH-Pressure (Mitchell 2023) actually showed

The IIH-Pressure trial (Mitchell JL et al., 2023, Brain^[1]) was a randomized, double-blind, parallel-group clinical trial conducted in the United Kingdom. Adult women with active IIH meeting modified Dandy criteria were randomized to subcutaneous exenatide 10 mcg twice daily or matched placebo for 12 weeks. The novel feature of the trial was the use of telemetric intracranial pressure monitoring — a chronically implanted pressure transducer that allowed serial ICP measurements at home, eliminating the need for repeat lumbar punctures and removing the noise associated with single LP measurements.

The primary endpoint was the change in ICP at 12 weeks at the 2.5-hour post-dose timepoint. The result on exenatide was approximately −5.7 cm H₂O vs placebo, statistically and clinically significant. The effect persisted at 24 hours and at 12 weeks, and — this is the load-bearing piece — the ICP reduction at 2.5 hours occurred before any meaningful change in body weight. Mean weight change between arms at 12 weeks was small. Headache frequency and severity also improved on exenatide, consistent with reduced ICP being the proximate cause of IIH headache.

The mechanism is biologically plausible. Botfield 2017 (Sci Transl Med^[5]) demonstrated GLP-1 receptor expression on the choroid plexus epithelium — the anatomic site of CSF secretion — and showed that exendin-4 reduced CSF secretion rate in a rat hydrocephalus model. The in-vivo human data from IIH-Pressure align with that preclinical pathway: less CSF in equals lower pressure.

A subsequent cognitive sub-analysis (Grech 2024, Eye^[6]) reported no cognitive decline on exenatide despite the coexisting use of acetazolamide and topiramate in many trial participants — a useful safety datapoint for patients already on the standard stack.

The standard IIH treatment stack

Modern IIH treatment is layered. The European Headache Federation guideline (Hoffmann/Mollan 2018, J Headache Pain^[7]) and the Markey 2023 Current Opinion in Neurology review^[9] describe a hierarchy:

1. Sustained weight loss of 5–10% of body weight. Sinclair 2010^[2] is the load-bearing observational evidence: women who lost ~15% over 3 months had documented ICP and papilledema reduction. The current era's GLP-1 toolkit (semaglutide, tirzepatide) can routinely deliver this magnitude of weight loss and is appropriate as the obesity-management pillar of IIH care, separately from any direct ICP effect.
2. Acetazolamide 500–4000 mg/day divided. NORDIC (Wall 2014^[3]) used titration up to 4 g/day as tolerated, with a mean dose around 2.5 g/day. Acetazolamide reduces CSF production via carbonic anhydrase inhibition at the choroid plexus. Side effects include paresthesias, dysgeusia (metallic taste), fatigue, kidney stones, and metabolic acidosis. It is contraindicated in pregnancy (Category C with first-trimester teratogenicity signals) and in sulfa allergy.
3. Topiramate 25–200 mg/day. A second-line option for patients intolerant to acetazolamide. Topiramate has weak carbonic anhydrase activity plus appetite suppression (which produces ~3–7% weight loss), making it attractive in IIH where the obesity pathway matters. The tradeoff is cognitive blunting, paresthesias, and a small kidney-stone risk.
4. Furosemide or methazolamide as third-line diuretic alternatives.
5. High-dose intravenous methylprednisolone for rapidly progressive visual loss as a bridge to surgery.
6. Therapeutic lumbar puncture for acute symptom relief, recognizing that CSF reaccumulates within hours and that LP is not a long-term strategy.
7. Surgical decompression for vision-threatening disease. Optic nerve sheath fenestration (ONSF), CSF diversion via ventriculoperitoneal or lumboperitoneal shunt, and venous sinus stenting for patients with documented transverse sinus stenosis and a pressure gradient.

Where GLP-1 fits in practice

For most IIH patients in 2026, a GLP-1 has two distinct rationales, and it is worth keeping them separate:

• The obesity-treatment rationale. Almost every IIH patient has obesity. A GLP-1 producing 15–20% sustained weight loss is well above the 5–10% threshold where the Sinclair 2010^[2] ICP and papilledema benefits emerge. This rationale applies to semaglutide (Wegovy/Ozempic), tirzepatide (Zepbound/Mounjaro), and oral orforglipron, and uses standard obesity-indication dosing.
• The IIH-specific mechanism rationale. The IIH-Pressure trial^[1] evidence is currently exenatide-specific. Whether the choroid plexus effect generalizes to semaglutide, tirzepatide, liraglutide, or orforglipron is plausible but not yet demonstrated in adequately powered human trials. The IIH-Pressure 2 and IIH-DT follow-up programs are expected to test this. Until those read out, “use exenatide for the IIH-specific mechanism” is an off-label decision a neurologist makes patient-by-patient, not a settled standard of care.

Practically, most IIH patients on acetazolamide who add a GLP-1 for weight loss tolerate the combination without specific interaction. The combination caution is topiramate plus a GLP-1 plus an SSRI/SNRI, because topiramate is already cognitively blunting and additive effects on word-finding, paresthesias, and mood can compound. Phentermine plus topiramate (Qsymia) plus a GLP-1 is a stack where the additive serotonergic and cognitive load is sometimes more than the patient bargained for — coordinate with neurology and obesity medicine rather than the patient stacking on their own.

Magnitude: ICP reduction at 12 weeks across interventions

Vision-threatening IIH: when GLP-1 is not the answer

The single most important clinical decision in IIH is whether the patient has vision-threatening disease. A patient with rapidly worsening papilledema, peripheral visual field constriction on automated perimetry, or a measured decline in Snellen acuity is a surgical patient, not a medication patient. ONSF or CSF diversion needs to be done within days to weeks, not after a 3-month medication trial. The Hoffmann/Mollan 2018 EHF guideline^[7] is explicit on this point.

Adding a GLP-1 to a vision-threatening IIH patient is not wrong, but it does not substitute for the surgical referral. A practical rule: if the neuro-ophthalmologist has scheduled surgery, the GLP-1 sits in the chronic-management column for after the procedure, not the acute-decompression column.

Pregnancy and contraception

IIH patients are predominantly reproductive-age women, which makes pregnancy considerations central. Acetazolamide is FDA Category C and is generally avoided in the first trimester. Topiramate is Category D for craniofacial malformations and cleft palate — not first-line in IIH patients of childbearing potential without effective contraception. GLP-1s are contraindicated in pregnancy and are typically held 2–3 months before planned conception. Patients on a GLP-1 for IIH plus weight management should have a clear contraception plan documented; the obstetric and neurologic consequences of an unplanned pregnancy on this stack are significant.

Cost and insurance landscape

IIH care is covered by US commercial insurance and Medicaid because it is a documented neurologic disease, but specific medications follow their own formulary logic. Acetazolamide is a generic ($20–50/month at most US pharmacies). Topiramate is also generic ($15–40/month). The GLP-1 component follows obesity-coverage rules — widely covered for type 2 diabetes (Ozempic, Mounjaro), variably covered for obesity alone (Wegovy, Zepbound), with prior authorization often required. Exenatide is currently the GLP-1 with the positive IIH-specific RCT but it is not FDA-approved for IIH; any insurance approval for exenatide-for-IIH is likely to be off-label and individualized.

Surgical IIH treatments are expensive. Optic nerve sheath fenestration runs about $20,000–30,000 facility plus surgeon fees; ventriculoperitoneal shunting and venous sinus stenting are in the same range or higher. These are typically covered when the indication is documented vision loss.

Provider pathway and follow-up

IIH care is a multidisciplinary problem. The minimum care team is a neurologist (often a headache neurologist), a neuro-ophthalmologist or comprehensive ophthalmologist for serial visual fields and OCT of the retinal nerve fiber layer, and an obesity medicine clinician or primary care physician managing the GLP-1 and weight-loss program. Neurosurgery enters when surgical decompression is on the table. Endocrinology can be helpful when the differential includes venous sinus thrombosis from a hypercoagulable state or when steroid use complicates the picture.

Follow-up cadence at a minimum is ophthalmology every 3 months during active disease (visual fields, OCT, fundus photos), neurology every 3–6 months for headache and medication titration, and an annual MRI/MRV for the first 2 years to confirm the diagnosis remains stable and no new structural pathology has emerged.

Related research

• GLP-1 for migraine — the companion piece on IIH-Pressure, CGRP-class stacking, and gepant PK
• GLP-1 brain fog and cognitive effects — relevant when stacking acetazolamide and topiramate on top of a GLP-1
• GLP-1 and tinnitus — pulsatile tinnitus is a classic IIH presenting symptom; the otolaryngology workup overlap is significant
• GLP-1 plus diuretics — furosemide is a third-line IIH option; potassium and renal monitoring matter
• GLP-1 vs bariatric surgery — bariatric surgery has long been used for refractory IIH; how to think about the choice today
• GLP-1 in older adults — IIH is overwhelmingly a younger-adult disease, but the sarcopenia framework applies to long-term weight management
• First 30 days on a GLP-1 — titration, side-effect management, and what to monitor in week 1 through week 4

Important disclaimer. This article is educational and does not constitute medical advice. Idiopathic intracranial hypertension is a vision-threatening neurologic disease that requires evaluation by a neurologist and a neuro-ophthalmologist or ophthalmologist with serial visual fields. Exenatide for IIH is currently off-label in the United States; the IIH-Pressure trial is a small randomized study and confirmatory programs are in progress. Acetazolamide and topiramate dosing should be individualized; patients with sulfa allergy, pregnancy potential, kidney stones, or cognitive concerns need careful prescriber review. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 6 months while IIH-Pressure 2 and IIH-DT confirmatory trial results are pending, then annually once the GLP-1 class effect on ICP is established or refuted.